NanoTag Biotechnologies

NanoTag Biotechnologies is a private, revenue-generating platform and services company specializing in the discovery, engineering, and production of single-domain antibodies (nanobodies). Its core business model combines a portfolio of validated research reagents (e.g., FluoTags®, Smart Secondaries®, Selector resins) with custom contract research services for sdAb discovery and protein production. The company has secured a significant strategic partnership with BioNTech to evaluate its proprietary ALFA labeling technology across therapeutic areas, indicating a strategic pivot towards therapeutic and diagnostic applications alongside its strong R&D tools business.

Integrated platform for single-domain antibody (sdAb/nanobody) discovery (proprietary Celline technology), engineering (FX technology), and application. Key technologies include the ALFA tagging/purification/labeling system, FluoTags® for imaging, Smart Secondaries®, and Selector affinity resins.

NanoTag competes in the research tools space against companies like ChromoTek (nanobody-based tools) and traditional antibody vendors developing recombinant formats. In the therapeutic sdAb platform arena, it faces competition from larger entities like Sanofi (via Ablynx) and a growing number of biotech startups. Its ALFA tag system competes with other established epitope tags (e.g., HA, FLAG) and newer systems like the SunTag.